Gadicke Ansbert's Form 4 filing
Werewolf Therapeutics, Inc. (HOWL) · filed Apr 30, 2025
- Accession no.
- 0001415889-25-011569
- Filed
- Apr 30, 2025, 4:08 PM ET
- Trade date
- Mar 27, 2025
- Filing delay
- 34 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 2 derivative transactions. Open-market sales total $4.61K. It was filed 34 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gadicke AnsbertCIK 0001134655 | 10% Owner |
| MPM Asset Management LLCCIK 0001263048 | 10% Owner |
| MPM BioImpact LLCCIK 0001687078 | 10% Owner |
| UBS Oncology Impact Fund L.P.CIK 0001691428 | 10% Owner |
| MPM Oncology Innovations Fund LPCIK 0001719960 | 10% Owner |
| Oncology Impact Fund (Cayman) Management L.P.CIK 0001721036 | 10% Owner |
| MPM Oncology Innovations Fund GP LLCCIK 0001857903 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 27, 2025 | Common Stock | XIn-the-money exerciseAcquired | +50,873 | $0.09 | +$4,578.57 | 6,723,056 | Indirect | |
| Mar 27, 2025 | Common Stock | SSaleDisposed | −4,386 | $1.05 | −$4,605.3 | 6,718,670 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 27, 2025 | Common Stock | XIn-the-money exerciseDisposed | −8,031 | $0.00 | $0 | 0 | Indirect | |
| Mar 27, 2025 | Common Stock | XIn-the-money exerciseDisposed | −42,842 | $0.00 | $0 | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.